Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of N-Methyl Pyrrolidine (Nmp). The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Methylpiperidine SCHEMBL28248315 | 0.97 | CA1 (0.39) | CA5ACA5BCYP1A2TDP1HTT | |
| N-Methylpiperidine SCHEMBL21616470 | 0.97 | CA1 (0.39) | CA5ACA5BCYP1A2TDP1HTT | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL28981661 | 0.91 | CYP2D6 (0.37) | CYP1A2TDP1HTTAPOBEC3AAPOBEC3G | |
| N-Methylpiperidine SCHEMBL6886194 | 0.88 | CYP2D6 (0.40) | CYP1A2TDP1HTTAPOBEC3AAPOBEC3G | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL16666459 | 0.88 | CYP2D6 (0.36) | CYP1A2TDP1HTTAPOBEC3AAPOBEC3G | |
| Sulfuric Acid SCHEMBL8471322 | 0.87 | CYP1A2 (0.48) | CA5ACA5BCYP1A2TDP1CA2 | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL23781395 | 0.86 | KMT2A (0.40) | CYP1A2TDP1HTTAPOBEC3AAPOBEC3G | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL11637810 | 0.84 | CYP1A2 (0.32) | CYP1A2TDP1HTTAPOBEC3AAPOBEC3G | |
| N-Methylpiperidine SCHEMBL28248312 | 0.82 | CA1 (0.33) | CYP1A2TDP1HTTAPOBEC3AAPOBEC3G | |
| Trifluoromethanesulfonic Acid SCHEMBL932992 | 0.82 | MAPK1 (0.33) | CYP1A2TDP1HTTAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822259-B1 | METHOD FOR SYNTHESIZING VALSARTAN | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2025-08-27 | — | — | EP | claimed |
| US-11434210-B2 | Method for synthesizing valsartan | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2022-09-06 | — | — | US | claimed |
| WO-2020010643-A1 | METHOD FOR SYNTHESIZING VALSARTAN | 浙江华海药业股份有限公司 | 2020-01-16 | — | — | WO | claimed |
| EP-3822259-B1 | METHOD FOR SYNTHESIZING VALSARTAN | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2025-08-27 | — | — | EP | disclosed |
| CN-113122380-B | Method for removing glycidyl ester by utilizing ionic liquid | 丰益(上海)生物技术研发中心有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-11434210-B2 | Method for synthesizing valsartan | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2022-09-06 | — | — | US | disclosed |
| US-20210277315-A1 | UPGRADING OF HEAVY OIL OR HEAVY OIL-DERIVED PRODUCT WITH IONIC LIQUIDS | SUNCOR ENERGY INC (CA) | 2021-09-09 | — | — | US | disclosed |
| CN-112638885-A | Synthesis method of valsartan | 浙江华海药业股份有限公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020010643-A1 | METHOD FOR SYNTHESIZING VALSARTAN | 浙江华海药业股份有限公司 | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434210-B2 | Method for synthesizing valsartan | REN, ACE, AGT | CA5A 3037/4885CA5B 3488/4885CYP1A2 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.